Physician Accreditation Statement

The Society for Pediatric Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  

Physician Credit Designation

The Society for Pediatric Pathology designates this Other activity (blended live activity and enduring material) for a maximum of 17.50 AMA PRA Category 1 Credits^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

American Board of Pathology (ABPath) Continuous Certification

This activity is registered for American Board of Pathology Lifelong Learning (CME) credit.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to satisfy the Lifelong Learning (CME) requirements in the American Board of Pathology’s (ABPath) Continuous Certification (CC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for purpose of granting credit.

Successful completion of the CME activity allows the participant to earn up to 17.50 Lifelong Learning (CME) credits.

To receive credit, you must complete the evaluation and provide your ABPath Diplomate ID and Date of Birth (MM/DD). Your information will be shared with the ABPath through the ACCME Program and Activity Reporting System (PARS).

Instructions to Receive CME Credit

All attendees should complete the session specific evaluations as related to those portions of the 2025 Fall Annual Meeting that were attended, as well as the overall conference evaluation. You must be logged into EthosCE in order to access the evaluations and claim credit. You must claim credit by September 26, 2026.

The chart below outlines which portions of the 2025 Fall Annual Meeting are offered for CME credit and the maximum number of credit hours a physician can earn for each portion accredited for AMA PRA Category 1 Credit™. As this is an “Other activity” format you may claim credit based on your attendance at either the live session or for watching the recorded session up through September 26, 2026 when recorded content will expire. However, you may not claim credit more than once for a given session. Those sessions that will be recorded are marked with an asterisk (*).

Contact Information

For questions regarding the accreditation of this meeting and the process for completing the evaluations and claiming credit, please contact the SPP at [email protected].

Available Credit

• 17.50 AMA PRA Category 1 Credit™
• 17.50 Participation Credit(s)

Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The Society for Pediatric Pathology does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Disclosure Information

The Society for Pediatric Pathology (SPP) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by SPP are required to disclose all financial relationships with any ineligible company within the past 24 months to the SPP. All financial relationships reported are identified as relevant and mitigated by the SPP in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by the SPP Education Committee to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by the SPP.

Planners and Managers

The following planners and managers have no relevant financial relationships with ineligible companies:

The following planners and managers have the following relevant financial relationships with ineligible companies:

M. Cristina Pacheco: Takeda Pharma, Contracted Research; Benjamin Wilkins: Sarepta Therapeutics, Consulting Fee

Faculty, Authors, Content Developers

The following faculty, authors, and content developers have no relevant financial relationships with ineligible companies:

M. Cristina Pacheco: Takeda Pharm (Contracted Research); Benjamin Wilkins: Sarepta Therapeutics (Consulting Fee;) Tamir Diamond: Mirum Pharmaceuticals, Sarepta Theraputic (Consulting Fee); Lisa Young: Boehringer Ingelheim (Consulting Fee), Wolters Kluwer (Royalty), UpToDate (Royalty); Jim Treat: UpToDate (Royalty), Andrews Diseases of the Skin (Royalty); Palvella Inc (Consulting Fee), Arcutis (Consulting Fee), Nektar (Consulting Fee), Incyte (Consulting Fee), Palvella (Contracted Research); Jessica Davis: Bayer Pharmaceutics (Consulting Fee), Presage Biosciences (Consulting Fee)

Moderators

The following moderators have no relevant financial relationships with ineligible companies:

Katte Carreon; Jonathan Slack; Shahrazad Saab; Diana Corao-Uribe; Katte Carreon; Erin Alston; Angela Viaene; Archana Shenoy; Jonathan Slack; Pierre Russo

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.